Medical Oncologist
When pazopanib stops working
When Pazopanib — Stops Working: What Comes Next
Pazopanib controls cancer by blocking the blood supply tumours need to grow. Over time, most tumours find ways around this — that is resistance, and it is expected. This page explains why it happens and what your oncologist can offer next.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Resistance is expected — Most patients on pazopanib will eventually develop resistance. It is a recognised feature of targeted therapy, not a sign that treatment failed.
- Options do not disappear — NCCN and ESMO both recognise established next-line pathways after pazopanib, including immunotherapy and other targeted drugs.
- Your cancer type determines the route — Next-line options differ between kidney cancer and soft tissue sarcoma. What fits you depends on your specific diagnosis and scan findings.
- The scan decides the timing — Progression is confirmed by imaging, not by how you feel. Scheduled scans matter even when you feel well.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Pazopanib can stop working as tumours find ways to grow around its effects — this is called acquired resistance. It does not mean treatment is over. NCCN and ESMO recognise several next-line options, including immunotherapy and other targeted drugs, that your oncologist can discuss based on your cancer type and health.
What do these words mean?
- Acquired resistance
- When a cancer that was initially responding to pazopanib finds ways to grow despite the drug still being given. This is different from the cancer never responding at all.
- Primary resistance
- When the first scan after starting pazopanib shows the cancer has grown rather than shrunk or stayed stable. Your oncologist may call this primary progression.
- Second-line therapy
- The treatment offered after the first drug stops working. It may be a different targeted drug, immunotherapy, chemotherapy, or a clinical trial.
- Cross-resistance
- When resistance to one VEGF-blocking drug reduces how well a similar drug works. It is partial, not complete, and does not apply equally to all next-line options.
- Re-staging
- Scans done after progression to assess how much the cancer has grown, where it has spread, and which next-line option fits best.
Why does pazopanib stop working over time?
Pazopanib works by blocking VEGF receptors — the signals that tell blood vessels to grow into a tumour. Without a blood supply, the tumour cannot grow easily.
Over time, some tumours activate alternative pathways that rebuild their blood supply in ways pazopanib cannot block. ESMO guidelines describe this as one of the main reasons targeted therapies have a finite period of effectiveness.
A second mechanism is that tumour cells can change, becoming less dependent on the pathways pazopanib targets. This is the cancer adapting, not the drug failing.
Primary resistance — where the cancer never responds from the start — is less common but also recognised. If your first scans showed growth, your oncologist will have moved quickly to explore alternatives.
What should you bring to the next-steps conversation?
- A list of any new symptoms since your last scan, even ones that seem minor
- Your most recent scan and blood test reports, or confirmation your team already has them
- A question about whether a clinical trial is open at your centre
- A note of any other medicines, supplements, or herbal remedies you are currently taking
- Someone who can listen and take notes alongside you
- A direct question for your oncologist: how urgent is the next decision for my situation?
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What are the next-line options after pazopanib?
The right next step depends on your cancer type, how fast the progression has been, and your overall health. There is no single answer that fits every patient.
For kidney cancer, NCCN and ESMO both recognise immunotherapy — particularly agents targeting the PD-1 pathway — and cabozantinib as well-established options after prior VEGFR-targeted treatment. Cabozantinib targets several pathways that tumours commonly activate when they develop resistance to drugs like pazopanib.
For soft tissue sarcoma, the options include different chemotherapy regimens and, in specific subtypes, other targeted agents. Your oncologist will explain which options apply to your sarcoma subtype.
In all situations, ask whether a clinical trial is open. Several trials are actively studying what works best after first-line targeted therapy, and enrolment does not require running out of standard options first.
Can you switch to a different targeted drug?
Cross-resistance between VEGFR inhibitors is partial, not complete. Switching to a different VEGFR-targeting drug can work, particularly if pazopanib was stopped for side effects rather than progression.
Where progression was the reason, your oncologist will usually prefer a drug that acts through a different mechanism — such as mTOR inhibition or immunotherapy — rather than another drug in the same class.
The sequencing decision weighs what you have had before, the pace of progression, your kidney and liver function, and what is covered or available. Ask your oncologist to explain the specific reasoning for the option they recommend.
Questions families ask when pazopanib stops working
Does resistance mean the cancer is now incurable?
Resistance to one treatment does not change the stage of your cancer or whether it was curable to begin with. It means one drug has stopped being effective and a different approach is needed. Many patients with kidney cancer receive several lines of treatment over a number of years. What matters is how fast the cancer is growing, your overall health, and how well the next treatment works for you.
How quickly do we need to make a decision?
This depends on how fast the cancer grew on scans and whether you have new symptoms. A rapidly growing tumour may prompt your oncologist to start the next treatment within days of the scan result. Slower progression often allows a week or two to review options, seek a second opinion, and decide thoughtfully. Ask your oncologist directly: how urgent is this for my situation?
Should we seek a second opinion?
Yes, and a confident oncologist will not be offended. Treatment sequencing after pazopanib involves weighing several options, and a second oncologist may know of a relevant trial or interpret the evidence differently. If travelling to another centre is difficult, ask whether a virtual second opinion is available. Keep a copy of your scan report and pathology to share easily.
Will the next treatment have worse side effects?
Different, not necessarily worse. Immunotherapy carries its own risk profile — immune reactions that can affect the gut, skin, lungs, or hormone glands — which is managed differently from the side effects of pazopanib. Chemotherapy has its own pattern. Your team will explain what to watch for before you start, so you know what is expected and what needs urgent reporting.
What if we do not want more aggressive treatment?
This is a legitimate position to discuss openly. Your oncologist should explain the expected benefit and side effects of the next option, and you have the right to weigh whether those match your priorities. If quality of life is the main priority, palliative and supportive care is a planned, medically supported pathway — not giving up. Ask to speak with a palliative care specialist if this is a direction you want to explore.
Is there anything we can do to slow or prevent resistance?
We do not yet know of a reliable way to prevent or delay acquired resistance in routine clinical practice. Researchers are studying combination approaches that may extend the time a treatment works, but none have become standard care. The most useful thing you can do is attend every scheduled scan so that progression is caught early — early detection keeps more next-line options available.
Explore 75 more Kidney, Ovarian & Sarcoma Targeted Medicines topics
Drug Deep Dive: Pazopanib (Votrient)
- Diarrhoea and Blood Pressure Rise on Pazopanib
- Diet and Nutrition While on Pazopanib
- Drug, Food and Supplement Interactions With Pazopanib
- Fertility, Pregnancy and Contraception on Pazopanib
- Hair Turning White and Skin Lightening on Pazopanib
- How Does Pazopanib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Pazopanib Take to Work?
- How Long Will You Stay on Pazopanib?
- Liver Toxicity on Pazopanib: Why LFTs Are Checked Every Two Weeks
- Pazopanib (Votrient, Pazonib): The Complete Patient Guide
- Pazopanib Combinations: Why It Is Usually Given Alone
- Pazopanib Myths: Hair Colour, Liver Damage and Stopping Early
- Pazopanib Price in India: Brand, Generic and Monthly Cost
- Pazopanib Side Effects: The Complete List and Timeline
- Pazopanib Success Rate and Survival: An Honest Look at the Numbers
- Pazopanib for Soft Tissue Sarcoma: What It Can and Cannot Do
- Pazopanib in Elderly Patients and Those With Other Illnesses
- Pazopanib in Kidney Cancer vs Sarcoma: Two Different Treatment Goals
- Pazopanib vs Sunitinib: Comparing Toxicity and Quality of Life
- Taking Pazopanib on an Empty Stomach: Why the Timing Rule Exists
- Tests and Monitoring While You Are on Pazopanib
- When Pazopanib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Pazopanib? Kidney Cancer and Soft Tissue Sarcoma
- Will Insurance or a Government Scheme Pay for Pazopanib?
- Work, Travel and Daily Life on Pazopanib
Drug Deep Dive: Olaparib (Lynparza)
- Adjuvant Olaparib After Early Breast Cancer Surgery
- Anaemia and Extreme Fatigue on Olaparib
- Blood Cancer Risk After Long-Term Olaparib: How Real Is It?
- Diet and Nutrition While on Olaparib
- Drug, Food and Supplement Interactions With Olaparib
- Fertility, Pregnancy and Contraception on Olaparib
- How Does Olaparib Work? The PARP Inhibitor Explained
- How Long Does Olaparib Take to Work?
- How Long Will You Stay on Olaparib?
- Maintenance Olaparib: Taking a Drug When There Is No Visible Cancer
- Nausea on Olaparib: Managing the Most Common Side Effect
- Olaparib (Lynparza, Olanib): The Complete Patient Guide
- Olaparib Myths: 'Only for BRCA', 'It's Chemo', 'It Causes Cancer'
- Olaparib Price in India: Brand, Generic and Monthly Cost
- Olaparib Side Effects: The Complete List and Timeline
- Olaparib Success Rate and Survival: An Honest Look at the Numbers
- Olaparib With Bevacizumab or Hormone Therapy: Combination Regimens
- Olaparib in Elderly Patients and Those With Other Illnesses
- Olaparib vs Niraparib vs Talazoparib: Comparing PARP Inhibitors
- Taking Olaparib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Olaparib
- When Olaparib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Olaparib? BRCA-Mutated Ovarian, Breast, Prostate and Pancreatic Cancer
- Will Insurance or a Government Scheme Pay for Olaparib?
- Work, Travel and Daily Life on Olaparib
Drug Deep Dive: Sunitinib (Sutent)
- Diet and Nutrition While on Sunitinib
- Drug, Food and Supplement Interactions With Sunitinib
- Fertility, Pregnancy and Contraception on Sunitinib
- Hand-Foot Skin Reaction on Sunitinib: Prevention From Day One
- How Does Sunitinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sunitinib Take to Work?
- How Long Will You Stay on Sunitinib?
- Mouth Sores, Taste Loss and Yellow Skin Discolouration on Sunitinib
- Sunitinib (Sutent, Sunitix): The Complete Patient Guide
- Sunitinib After Kidney Surgery and for GIST: Two Different Settings
- Sunitinib Myths: Hair Colour Change, Dose Cuts and 'Weaker Treatment'
- Sunitinib Price in India: Brand, Generic and Monthly Cost
- Sunitinib Side Effects: The Complete List and Timeline
- Sunitinib Success Rate and Survival: An Honest Look at the Numbers
- Sunitinib and Immunotherapy: Where Combinations Fit in Kidney Cancer
- Sunitinib in Elderly Patients and Those With Other Illnesses
- Sunitinib vs Pazopanib vs Cabozantinib for Kidney Cancer
- Taking Sunitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sunitinib
- The 4-Weeks-On, 2-Weeks-Off Sunitinib Schedule and the 2/1 Alternative
- Thyroid Failure and Fatigue on Sunitinib: The Test to Repeat Every Cycle
- When Sunitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sunitinib? Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumours
- Will Insurance or a Government Scheme Pay for Sunitinib?
- Work, Travel and Daily Life on Sunitinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How will my oncologist know pazopanib has stopped working?
The main signal is a scan showing the cancer has grown or spread since the previous scan. Your oncologist may also act if new symptoms appear between scheduled scans. Blood tests and tumour markers alone are rarely enough to confirm progression — imaging is usually required. This is why scheduled scans matter even when you feel well: catching progression early keeps more options available.
Is progression on pazopanib a sign that immunotherapy will work?
Not automatically. Response to immunotherapy depends on the biology of your specific tumour — markers such as PD-L1 expression — not on whether a previous targeted drug worked or stopped working. For kidney cancer, NCCN guidelines support immunotherapy after prior anti-angiogenic treatment, but it does not work for every patient. Your oncologist may order biomarker testing to assess whether it is likely to help in your case before recommending it.
Can pazopanib be restarted after a break?
In some situations, yes. There are published case reports of patients who benefited from restarting pazopanib after an interval on a different treatment. This is more likely to be considered when pazopanib was stopped for side effects rather than clear progression. It is not a standard approach, and your oncologist will weigh whether it makes sense for your specific situation. It is a reasonable question to raise at your next appointment.
Will the next treatment be covered by insurance or a government scheme?
Coverage depends on the specific drug, your insurer, and whether the drug is approved by CDSCO for your indication. Some next-line drugs — particularly newer immunotherapy agents — may need prior authorisation or may not be covered for every cancer type. Ask your oncologist and the hospital billing team to check coverage before you decide, so cost is part of the full picture and not a surprise after you start.
How many lines of treatment are typically available?
There is no fixed number. It depends on your cancer type, how each treatment worked, and how your health has held up. For kidney cancer, sequential treatment across three or more lines is not unusual in current practice. For soft tissue sarcoma, the options narrow more quickly. Ask your oncologist to sketch the likely sequence for your situation — understanding the road ahead, not just the next step, helps you plan.
What happens at CION when pazopanib stops working?
Your CION oncologist will review the scan result, discuss the next-line options relevant to your cancer type, and coordinate the next treatment. If immunotherapy is recommended, it can be given as day care at CION centres. Re-staging PET-CT is coordinated with partner imaging centres. If a clinical trial is relevant, your team will tell you whether one is open at your centre. CION does not provide CAR-T or cell therapy; if that is discussed, you would be referred to a centre that offers it.